Seizures-Pipeline Review, H1 2015

Seizures-Pipeline Review, H1 2015

  • Products Id :- GMDHC6147IDB
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Seizures-Pipeline Review, H1 2015


Global Markets Direct's, 'Seizures-Pipeline Review, H1 2015', provides an overview of the Seizures's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Seizures

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Seizures and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Seizures products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Seizures pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Seizures

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Seizures Overview 8

Therapeutics Development 9

Pipeline Products for Seizures-Overview 9

Pipeline Products for Seizures-Comparative Analysis 10

Seizures-Therapeutics under Development by Companies 11

Seizures-Therapeutics under Investigation by Universities/Institutes 13

Seizures-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Seizures-Products under Development by Companies 17

Seizures-Products under Investigation by Universities/Institutes 18

Seizures-Companies Involved in Therapeutics Development 19

Acorda Therapeutics, Inc. 19

Advicenne Pharma 20

Alexza Pharmaceuticals, Inc. 21

Concert Pharmaceuticals, Inc. 22

Neurelis, Inc. 23

Novartis AG 24

Pfizer Inc. 25

Sage Therapeutics 26

Ultragenyx Pharmaceutical Inc. 27

Upsher-Smith Laboratories, Inc. 28

Seizures-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

ADV-6208-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

alprazolam-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

C-10068-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CCG-63802-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CHEC-9-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

diazepam-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

diazepam-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

diazepam-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

everolimus-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

midazolam hydrochloride-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

SAGE-217-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

UX-007-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Seizures-Recent Pipeline Updates 60

Seizures-Dormant Projects 70

Seizures-Discontinued Products 71

Seizures-Product Development Milestones 72

Featured News & Press Releases 72

Sep 02, 2014: SAGE Therapeutics Presents New Preclinical Data on SAGE-217 at Eilat Conference on New Anti-Epileptic Drugs 72

Nov 01, 2013: Systematic Review Finds Intranasal Midazolam Comparable To Intravenous Or Rectal Administration Of Diazepam For Treatment Of Acute Seizure Emergencies In Pediatric Patients 72

Jun 24, 2013: Upsher-Smith Labs Announces Patient Enrollment In Open-label Safety Study Of USL261 For Rescue Treatment Of Seizure Clusters In Epilepsy 73

May 06, 2013: Alexza Pharma To Present Data On AZ-002 At Antiepileptic Drug And Device Trials Conference 74

Mar 19, 2013: Upsher-Smith Labs Presents Favorable Phase I Data For USL261 At 65th Annual Meeting Of AAN 74

Nov 26, 2012: Upsher-Smith Labs Presents Clinical Data On Midazolam At American Epilepsy Society Annual Meeting 75

Apr 26, 2012: Upsher-Smith Provides Update On Phase III Seizure Clusters Study 76

Appendix 78

Methodology 78

Coverage 78

Secondary Research 78

Primary Research 78

Expert Panel Validation 78

Contact Us 78

Disclaimer 79

List of Tables

Number of Products under Development for Seizures, H1 2015 9

Number of Products under Development for Seizures-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Seizures-Pipeline by Acorda Therapeutics, Inc., H1 2015 19

Seizures-Pipeline by Advicenne Pharma, H1 2015 20

Seizures-Pipeline by Alexza Pharmaceuticals, Inc., H1 2015 21

Seizures-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 22

Seizures-Pipeline by Neurelis, Inc., H1 2015 23

Seizures-Pipeline by Novartis AG, H1 2015 24

Seizures-Pipeline by Pfizer Inc., H1 2015 25

Seizures-Pipeline by Sage Therapeutics, H1 2015 26

Seizures-Pipeline by Ultragenyx Pharmaceutical Inc., H1 2015 27

Seizures-Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Seizures Therapeutics-Recent Pipeline Updates, H1 2015 60

Seizures-Dormant Projects, H1 2015 70

Seizures-Discontinued Products, H1 2015 71

List of Figures

Number of Products under Development for Seizures, H1 2015 9

Number of Products under Development for Seizures-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 30

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Acorda Therapeutics, Inc.

Advicenne Pharma

Alexza Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc.

Neurelis, Inc.

Novartis AG

Pfizer Inc.

Sage Therapeutics

Ultragenyx Pharmaceutical Inc.

Upsher-Smith Laboratories, Inc.

Seizures Therapeutic Products under Development, Key Players in Seizures Therapeutics, Seizures Pipeline Overview, Seizures Pipeline, Seizures Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]